A Study to Identify Participants With Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations

计划入组 3,679 人 · 首次发布于 2019 年 5 月 20 日

Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)

计划入组 168 人 · 首次发布于 2013 年 11 月 6 日

Expanded Access for Vepugratinib (LY3866288) in Participants With Fibroblast Growth Factor Receptor 3 (FGFR3) Altered Solid Tumors

首次发布于 2026 年 6 月 30 日

fibroblast growth factor receptor-3 inhibitor (oral, achondroplasia)

Fibroblast Growth Factor Receptor-3 Antibodies (Progenika Biopharma)

Recifercept

TYRA BIOSCIENCES, INC.

United States

Arvinas Estrogen Receptor, Inc.

United States

Arvinas Androgen Receptor, Inc.

United States

FDA Grants Priority Review to Nintedanib for Idiopathic Pulmonary Fibrosis

HARMONICARE Receives FDA Approval for FGFR2/3 Inhibitor ABSK061 Clinical Trial in Pediatric Achondroplasia

Japan Recommends Approval for Brukinsa and Balversa; Grants Sakigake Designation to Brogidirsen and Iclepertin